Targeting EGFR signaling through EGFR inhibitors profoundly impairs the tumor progression [57]; however, monoclonal antibodies blocking the ligand binding to EGFR, have shown modest activity as a single agent in patients with metastatic colorectal cancer in clinical trials. Here, EGFR is linked to neoplasm.